Analysts See $-0.89 EPS for Aclaris Therapeutics Inc (ACRS)

October 14, 2017 - By Winifred Garcia

 Analysts See $ 0.89 EPS for Aclaris Therapeutics Inc (ACRS)

Investors wait Aclaris Therapeutics Inc (NASDAQ:ACRS) to report on November, 2. its quarterly earnings Wall Street analysts expect $-0.89 EPS, down $0.39 or 78.00 % from last year’s $-0.5 same quarter earnings. Aclaris Therapeutics Inc’s Wall Street analysts see 58.93 % negative EPS growth, taking into account the $-0.56 EPS reproted in the previous quarter, The stock decreased 1.54% or $0.41 during the last trading session, reaching $26.14. About 170,959 shares traded. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 25.57% since October 14, 2016 and is uptrending. It has outperformed by 8.87% the S&P500.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 13 analyst reports since November 2, 2015 according to SRatingsIntel. JMP Securities initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) on Friday, September 30 with “Market Perform” rating. The firm earned “Buy” rating on Monday, June 26 by Jefferies. The firm has “Buy” rating by Citigroup given on Monday, November 2. The company was maintained on Friday, August 12 by Jefferies. The firm has “Buy” rating given on Friday, June 10 by Guggenheim. The firm has “Buy” rating given on Monday, September 19 by Jefferies. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Buy” rating by Jefferies on Thursday, August 31. The firm has “Outperform” rating given on Monday, November 2 by William Blair. On Wednesday, August 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Buy” rating on Monday, November 2 by Jefferies.

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The company has market cap of $784.11 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Firm is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

More notable recent Aclaris Therapeutics Inc (NASDAQ:ACRS) news were published by: Seekingalpha.com which released: “Aclaris: Bright Future Ahead With Dermatology And Alopecia Treatments” on July 18, 2017, also Seekingalpha.com with their article: “Aclaris Therapeutics’ (ACRS) CEO Dr. Neal Walker on Q2 2017 Results – Earnings …” published on August 11, 2017, Nasdaq.com published: “Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.” on August 08, 2017. More interesting news about Aclaris Therapeutics Inc (NASDAQ:ACRS) were released by: Globenewswire.com and their article: “Aclaris Therapeutics Announces Issuance of Two US Patents Covering JAK …” published on September 05, 2017 as well as Globenewswire.com‘s news article titled: “Aclaris Therapeutics Reports First Quarter 2017 Financial Results” with publication date: May 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com